Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.

Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, Simon LS, Strand V, Lipsky PE.

Arthritis Rheumatol. 2018 Apr 12. doi: 10.1002/art.40522. [Epub ahead of print]

PMID:
29648686
2.

A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system.

Gavin PD, Simon LS, Schlagheck T, Smith AJ, Krishnarajah J.

Pain Manag. 2017 Nov;7(6):499-512. doi: 10.2217/pmt-2017-0032. Epub 2017 Aug 17.

PMID:
28814158
3.

Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets.

Tunis SR, Maxwell LJ, Graham ID, Shea BJ, Beaton DE, Bingham CO 3rd, Brooks P, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2017 Oct;44(10):1551-1559. doi: 10.3899/jrheum.161273. Epub 2017 Aug 1.

PMID:
28765256
4.

The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica.

Mackie SL, Twohig H, Neill LM, Harrison E, Shea B, Black RJ, Kermani TA, Merkel PA, Mallen CD, Buttgereit F, Mukhtyar C, Simon LS, Hill CL; OMERACT PMR Working Group.

J Rheumatol. 2017 Oct;44(10):1515-1521. doi: 10.3899/jrheum.161109. Epub 2017 Aug 1.

PMID:
28765246
5.

Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study.

Gavin PD, Simon LS, Schlagheck T, Smith AJ, Shakib S.

Pain Manag. 2017 Jul;7(4):243-253. doi: 10.2217/pmt-2016-0068. Epub 2017 Apr 19.

PMID:
28421874
6.

A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group.

Black RJ, Robson JC, Goodman SM, Hoon E, Lai LYH, Simon LS, Harrison E, Neill L, Richards P, Nelsen LM, Nebesky JM, Mackie SL, Hill CL.

J Rheumatol. 2017 Nov;44(11):1754-1758. doi: 10.3899/jrheum.161083. Epub 2017 Apr 1.

7.

Perceptual attributes for the comparison of head-related transfer functions.

Simon LS, Zacharov N, Katz BF.

J Acoust Soc Am. 2016 Nov;140(5):3623.

PMID:
27908072
8.

Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.

Klokker L, Tugwell P, Furst DE, Devoe D, Williamson P, Terwee CB, Suarez-Almazor ME, Strand V, Woodworth T, Leong AL, Goel N, Boers M, Brooks PM, Simon LS, Christensen R.

J Rheumatol. 2017 Dec;44(12):1916-1919. doi: 10.3899/jrheum.161105. Epub 2016 Oct 15.

PMID:
27744393
9.

Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT).

de Wit M, Kirwan JR, Tugwell P, Beaton D, Boers M, Brooks P, Collins S, Conaghan PG, D'Agostino MA, Hofstetter C, Hughes R, Leong A, Lyddiatt A, March L, May J, Montie P, Richards P, Simon LS, Singh JA, Strand V, Voshaar M, Bingham CO 3rd, Gossec L.

Patient. 2017 Apr;10(2):141-152. doi: 10.1007/s40271-016-0198-4.

10.

A critical review of clinical trials in systemic lupus erythematosus.

Mahieu MA, Strand V, Simon LS, Lipsky PE, Ramsey-Goldman R.

Lupus. 2016 Sep;25(10):1122-40. doi: 10.1177/0961203316652492. Review.

11.

Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.

Edwards RR, Dworkin RH, Turk DC, Angst MS, Dionne R, Freeman R, Hansson P, Haroutounian S, Arendt-Nielsen L, Attal N, Baron R, Brell J, Bujanover S, Burke LB, Carr D, Chappell AS, Cowan P, Etropolski M, Fillingim RB, Gewandter JS, Katz NP, Kopecky EA, Markman JD, Nomikos G, Porter L, Rappaport BA, Rice AS, Scavone JM, Scholz J, Simon LS, Smith SM, Tobias J, Tockarshewsky T, Veasley C, Versavel M, Wasan AD, Wen W, Yarnitsky D.

Pain. 2016 Sep;157(9):1851-71. doi: 10.1097/j.pain.0000000000000602. Review.

12.

Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations.

Taylor AM, Phillips K, Patel KV, Turk DC, Dworkin RH, Beaton D, Clauw DJ, Gignac MA, Markman JD, Williams DA, Bujanover S, Burke LB, Carr DB, Choy EH, Conaghan PG, Cowan P, Farrar JT, Freeman R, Gewandter J, Gilron I, Goli V, Gover TD, Haddox JD, Kerns RD, Kopecky EA, Lee DA, Malamut R, Mease P, Rappaport BA, Simon LS, Singh JA, Smith SM, Strand V, Tugwell P, Vanhove GF, Veasley C, Walco GA, Wasan AD, Witter J.

Pain. 2016 Sep;157(9):1836-50. doi: 10.1097/j.pain.0000000000000577. Review.

13.

Ms. A.M. Taylor, et al reply.

Taylor AM, Taylor JO, Singh JA, Conaghan PG, Choy EH, Tugwell PS, Kaiser U, Strand V, Simon LS, Mease PJ.

J Rheumatol. 2016 Apr;43(4):826. doi: 10.3899/jrheum.151456. No abstract available.

14.

To branch out or stay focused? Affective shifts differentially predict organizational citizenship behavior and task performance.

Yang LQ, Simon LS, Wang L, Zheng X.

J Appl Psychol. 2016 Jun;101(6):831-45. doi: 10.1037/apl0000088. Epub 2016 Feb 15.

PMID:
26882443
15.

Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group.

Helliwell T, Brouwer E, Pease CT, Hughes R, Hill CL, Neill LM, Halls S, Simon LS, Mallen CD, Boers M, Kirwan JR, Mackie SL.

J Rheumatol. 2016 Jan;43(1):182-6. doi: 10.3899/jrheum.141179. Epub 2015 Nov 15. Review.

16.

Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda.

Maxwell LJ, Wells GA, Simon LS, Conaghan PG, Grosskleg S, Scrivens K, Beaton DE, Bingham CO 3rd, Busse JW, Christensen R, Goel N, Jüni P, Kaiser U, Lyddiatt A, Mease PJ, Ostelo RW, Phillips K, Sapunar D, Singh JA, Strand V, Taylor AM, Terwee CB, Tugwell P.

J Rheumatol. 2015 Oct;42(10):1934-1942. doi: 10.3899/jrheum.141423. Epub 2015 Sep 15.

PMID:
26373562
17.

Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT.

Phillips K, Taylor A, Mease PJ, Simon LS, Conaghan PG, Choy EH, Singh JA, Strand V, Gossec L, Kaiser U, de Wit M, Ostelo R, Maxwell L, Tugwell PS.

J Rheumatol. 2015 Oct;42(10):1943-1946. doi: 10.3899/jrheum.141386. Epub 2015 Aug 1.

PMID:
26233508
18.

Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain.

Taylor AM, Phillips K, Taylor JO, Singh JA, Conaghan PG, Choy EH, Tugwell PS, Kaiser U, Strand V, Simon LS, Mease PJ.

J Rheumatol. 2015 Oct;42(10):1947-1953. doi: 10.3899/jrheum.141328. Epub 2015 Jul 1.

PMID:
26136483
19.

Understanding cycles of abuse: A multimotive approach.

Simon LS, Hurst C, Kelley K, Judge TA.

J Appl Psychol. 2015 Nov;100(6):1798-810. doi: 10.1037/apl0000031. Epub 2015 May 25.

PMID:
26011719
21.

OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hand osteoarthritis.

Kloppenburg M, Maheu E, Kraus VB, Cicuttini F, Doherty M, Dreiser RL, Henrotin Y, Jiang GL, Mandl L, Martel-Pelletier J, Nelson AE, Neogi T, Pelletier JP, Punzi L, Ramonda R, Simon LS, Wang S; OARSI Hand Clinical Trial Recommendations Work Group.

Osteoarthritis Cartilage. 2015 May;23(5):772-86. doi: 10.1016/j.joca.2015.03.007. Review.

22.

OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hip osteoarthritis.

Lane NE, Hochberg MC, Nevitt MC, Simon LS, Nelson AE, Doherty M, Henrotin Y, Flechsenhar K.

Osteoarthritis Cartilage. 2015 May;23(5):761-71. doi: 10.1016/j.joca.2015.03.006. Review. Erratum in: Osteoarthritis Cartilage. 2015 Oct;23(10):1821. Herontin, Yves [Corrected to Henrotin, Yves].

23.
24.

Dialogue on Developing Consensus on Measurement and Presentation of Patient-important Outcomes, Using Pain Outcomes as an Exemplar, in Systematic Reviews: A Preconference Meeting at OMERACT 12.

Tugwell PS, Maxwell LJ, Beaton DE, Busse JW, Christensen R, Conaghan PG, Simon LS, Terwee C, Tovey D, Wells GA, Williamson P.

J Rheumatol. 2015 Oct;42(10):1931-1933. doi: 10.3899/jrheum.141430. Epub 2015 Feb 1.

PMID:
25641896
25.

Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group.

Grainger R, Dalbeth N, Keen H, Durcan L, Lawrence Edwards N, Perez-Ruiz F, Diaz-Torne C, Singh JA, Khanna D, Simon LS, Taylor WJ.

J Rheumatol. 2015 Dec;42(12):2460-4. doi: 10.3899/jrheum.141164. Epub 2015 Feb 1. Review.

26.

Development of a bedside pain assessment kit for the classification of patients with osteoarthritis.

Osgood E, Trudeau JJ, Eaton TA, Jensen MP, Gammaitoni A, Simon LS, Katz N.

Rheumatol Int. 2015 Jun;35(6):1005-13. doi: 10.1007/s00296-014-3191-z. Epub 2014 Dec 16.

PMID:
25510290
27.

Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication.

Markman JD, Frazer ME, Rast SA, McDermott MP, Gewandter JS, Chowdhry AK, Czerniecka K, Pilcher WH, Simon LS, Dworkin RH.

Neurology. 2015 Jan 20;84(3):265-72. doi: 10.1212/WNL.0000000000001168. Epub 2014 Dec 10.

28.

The regulatory perspective.

Simon LS.

J Peripher Nerv Syst. 2014 Oct;19 Suppl 2:S15-6. doi: 10.1111/jns.12081_1. No abstract available.

PMID:
25269731
29.

Meta-analysis of assay sensitivity and study features in clinical trials of pharmacologic treatments for osteoarthritis pain.

Dworkin RH, Turk DC, Peirce-Sandner S, He H, McDermott MP, Hochberg MC, Jordan JM, Katz NP, Lin AH, Neogi T, Rappaport BA, Simon LS, Strand V.

Arthritis Rheumatol. 2014 Dec;66(12):3327-36. doi: 10.1002/art.38869.

30.

Trial evidence and approval of therapeutic agents.

Green AM, Simon LS.

JAMA. 2014 May;311(20):2128-9. doi: 10.1001/jama.2014.3401. No abstract available.

PMID:
24867019
31.

Updating the OMERACT filter: implications for imaging and soluble biomarkers.

D'Agostino MA, Boers M, Kirwan J, van der Heijde D, Østergaard M, Schett G, Landewé RB, Maksymowych WP, Naredo E, Dougados M, Iagnocco A, Bingham CO 3rd, Brooks PM, Beaton DE, Gandjbakhch F, Gossec L, Guillemin F, Hewlett SE, Kloppenburg M, March L, Mease PJ, Moller I, Simon LS, Singh JA, Strand V, Wakefield RJ, Wells GA, Tugwell P, Conaghan PG.

J Rheumatol. 2014 May;41(5):1016-24. doi: 10.3899/jrheum.131313. Epub 2014 Mar 1.

32.

Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.

Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, Conaghan PG, Bingham CO 3rd, Brooks P, Landewé R, March L, Simon LS, Singh JA, Strand V, Tugwell P.

J Clin Epidemiol. 2014 Jul;67(7):745-53. doi: 10.1016/j.jclinepi.2013.11.013. Epub 2014 Feb 28.

33.

Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR.

Mackie SL, Arat S, da Silva J, Duarte C, Halliday S, Hughes R, Morris M, Pease CT, Sherman JW, Simon LS, Walsh M, Westhovens R, Zakout S, Kirwan JR.

J Rheumatol. 2014 Apr;41(4):819-23. doi: 10.3899/jrheum.131254. Epub 2014 Feb 1. Review.

PMID:
24488422
34.

Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout.

Taylor WJ, Redden D, Dalbeth N, Schumacher HR, Edwards NL, Simon LS, John MR, Essex MN, Watson DJ, Evans R, Rome K, Singh JA.

J Rheumatol. 2014 Mar;41(3):574-80. doi: 10.3899/jrheum.131245. Epub 2014 Jan 15.

35.

OMERACT 11: international consensus conference on outcome measures in rheumatology.

Simon LS, Strand V, Bingham CO 3rd, Singh JA.

J Rheumatol. 2014 Jan;41(1):145-9. doi: 10.3899/jrheum.130937. No abstract available.

PMID:
24382928
36.

Advice from professional societies: appropriate use of NSAIDs.

Meara AS, Simon LS.

Pain Med. 2013 Dec;14 Suppl 1:S3-10. doi: 10.1111/pme.12282. Review.

PMID:
24373108
37.

OMERACT endorsement of measures of outcome for studies of acute gout.

Singh JA, Taylor WJ, Dalbeth N, Simon LS, Sundy J, Grainger R, Alten R, March L, Strand V, Wells G, Khanna D, McQueen F, Schlesinger N, Boonen A, Boers M, Saag KG, Schumacher HR, Edwards NL.

J Rheumatol. 2014 Mar;41(3):569-73. doi: 10.3899/jrheum.131246. Epub 2013 Dec 15.

38.

Nonsteroidal anti-inflammatory drugs and their risk: a story still in development.

Simon LS.

Arthritis Res Ther. 2013;15 Suppl 3:S1. doi: 10.1186/ar4173. Epub 2013 Jul 24.

39.

What I experienced yesterday is who I am today: relationship of work motivations and behaviors to within-individual variation in the five-factor model of personality.

Judge TA, Simon LS, Hurst C, Kelley K.

J Appl Psychol. 2014 Mar;99(2):199-221. doi: 10.1037/a0034485. Epub 2013 Oct 7.

PMID:
24099348
40.

Hierarchical representations of the five-factor model of personality in predicting job performance: integrating three organizing frameworks with two theoretical perspectives.

Judge TA, Rodell JB, Klinger RL, Simon LS, Crawford ER.

J Appl Psychol. 2013 Nov;98(6):875-925. doi: 10.1037/a0033901. Epub 2013 Sep 9.

PMID:
24016206
41.

Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk.

Moore RA, Derry S, Simon LS, Emery P.

Pain Pract. 2014 Apr;14(4):378-95. doi: 10.1111/papr.12100. Epub 2013 Aug 14. Review.

42.

GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial.

Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF.

Am J Gastroenterol. 2013 Mar;108(3):392-400. doi: 10.1038/ajg.2012.467. Epub 2013 Feb 12.

43.

An examination of preactivity and postactivity stretching practices of NCAA division I, NCAA division II, and NCAA division III track and field throws programs.

Judge LW, Bellar DM, Gilreath EL, Petersen JC, Craig BW, Popp JK, Hindawi OS, Simon LS.

J Strength Cond Res. 2013 Oct;27(10):2691-9. doi: 10.1519/JSC.0b013e318280c9ac.

PMID:
23254548
44.

An examination of preactivity and postactivity stretching practices of crosscountry and track and field distance coaches.

Judge LW, Petersen JC, Bellar DM, Craig BW, Wanless EA, Benner M, Simon LS.

J Strength Cond Res. 2013 Sep;27(9):2456-64. doi: 10.1519/JSC.0b013e318257703c.

PMID:
22505134
45.

Treatment of osteoarthritis with continuous versus intermittent celecoxib.

Strand V, Simon LS, Dougados M, Sands GH, Bhadra P, Breazna A, Immitt J.

J Rheumatol. 2011 Dec;38(12):2625-34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1.

PMID:
22045833
46.

Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update.

Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA, Simon LS, Strand V, Williams DA, Arnold LM; OMERACT Fibromyalgia Working Group.

J Rheumatol. 2011 Jul;38(7):1487-95. doi: 10.3899/jrheum.110277.

47.

Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials.

Taylor WJ, Singh JA, Saag KG, Dalbeth N, MacDonald PA, Edwards NL, Simon LS, Stamp LK, Neogi T, Gaffo AL, Khanna PP, Becker MA, Schumacher HR Jr.

J Rheumatol. 2011 Jul;38(7):1467-70. doi: 10.3899/jrheum.110274.

PMID:
21724718
48.

Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?

Stamp LK, Khanna PP, Dalbeth N, Boers M, Maksymowych WP, Schumacher HR Jr, Becker MA, MacDonald PA, Edwards NL, Singh JA, Simon LS, McQueen FM, Neogi T, Gaffo AL, Strand V, Taylor WJ.

J Rheumatol. 2011 Jul;38(7):1462-6. doi: 10.3899/jrheum.110273.

49.

Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities.

Dalbeth N, McQueen FM, Singh JA, MacDonald PA, Edwards NL, Schumacher HR Jr, Simon LS, Stamp LK, Neogi T, Gaffo AL, Khanna PP, Becker MA, Taylor WJ.

J Rheumatol. 2011 Jul;38(7):1458-61. doi: 10.3899/jrheum.110272.

50.

Patient-reported outcomes in chronic gout: a report from OMERACT 10.

Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, Neogi T, Gaffo AL, Becker MA, MacDonald PA, Dabbous O, Strand V, Dalbeth ND, Aletaha D, Edwards NL, Schumacher HR Jr.

J Rheumatol. 2011 Jul;38(7):1452-7. doi: 10.3899/jrheum.110271.

Supplemental Content

Loading ...
Support Center